183 related articles for article (PubMed ID: 29385703)
1. CERA Attenuates Kidney Fibrogenesis in the db/db Mouse by Influencing the Renal Myofibroblast Generation.
Fischer C; Deininger N; Wolf G; Loeffler I
J Clin Med; 2018 Jan; 7(2):. PubMed ID: 29385703
[TBL] [Abstract][Full Text] [Related]
2. FSP1-specific SMAD2 knockout in renal tubular, endothelial, and interstitial cells reduces fibrosis and epithelial-to-mesenchymal transition in murine STZ-induced diabetic nephropathy.
Loeffler I; Liebisch M; Allert S; Kunisch E; Kinne RW; Wolf G
Cell Tissue Res; 2018 Apr; 372(1):115-133. PubMed ID: 29209813
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse.
Loeffler I; Rüster C; Franke S; Liebisch M; Wolf G
Am J Physiol Renal Physiol; 2013 Sep; 305(6):F911-8. PubMed ID: 23825071
[TBL] [Abstract][Full Text] [Related]
4. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury.
Menne J; Park JK; Shushakova N; Mengel M; Meier M; Fliser D
J Am Soc Nephrol; 2007 Jul; 18(7):2046-53. PubMed ID: 17554150
[TBL] [Abstract][Full Text] [Related]
5. Renal tubulointerstitial fibrosis in OVE26 type 1 diabetic mice.
Powell DW; Bertram CC; Cummins TD; Barati MT; Zheng S; Epstein PN; Klein JB
Nephron Exp Nephrol; 2009; 111(1):e11-9. PubMed ID: 19052473
[TBL] [Abstract][Full Text] [Related]
6. Chronic erythropoietin treatment affects different molecular pathways of diabetic cardiomyopathy in mouse.
Shushakova N; Park JK; Menne J; Fliser D
Eur J Clin Invest; 2009 Sep; 39(9):755-60. PubMed ID: 19614950
[TBL] [Abstract][Full Text] [Related]
7. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
Hong SW; Isono M; Chen S; Iglesias-De La Cruz MC; Han DC; Ziyadeh FN
Am J Pathol; 2001 May; 158(5):1653-63. PubMed ID: 11337363
[TBL] [Abstract][Full Text] [Related]
8. Transformation of interstitial fibroblasts and tubulointerstitial fibrosis in diabetic nephropathy.
Ina K; Kitamura H; Tatsukawa S; Takayama T; Fujikura Y; Shimada T
Med Electron Microsc; 2002 Jun; 35(2):87-95. PubMed ID: 12181650
[TBL] [Abstract][Full Text] [Related]
9. Pericyte activation accompanied by peritubular capillaries dysfunction and pericyte-to-myofibroblast transition is associated with renal fibrosis in diabetic nephropathy.
Feng Y; Tian D; Bai Y; Li Y; Zhang L; Wu Y; Liu W; Diao Z
Kidney Res Clin Pract; 2024 Feb; ():. PubMed ID: 38325871
[TBL] [Abstract][Full Text] [Related]
10. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis.
Okada H; Kikuta T; Kobayashi T; Inoue T; Kanno Y; Takigawa M; Sugaya T; Kopp JB; Suzuki H
J Am Soc Nephrol; 2005 Jan; 16(1):133-43. PubMed ID: 15574513
[TBL] [Abstract][Full Text] [Related]
11. Effect of echinacoside on kidney fibrosis by inhibition of TGF-β1/Smads signaling pathway in the db/db mice model of diabetic nephropathy.
Tang F; Hao Y; Zhang X; Qin J
Drug Des Devel Ther; 2017; 11():2813-2826. PubMed ID: 29033543
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin prevents diabetes-induced podocyte damage.
Schiffer M; Park JK; Tossidou I; Bartels J; Shushakova N; Menne J; Fliser D
Kidney Blood Press Res; 2008; 31(6):411-5. PubMed ID: 19096223
[TBL] [Abstract][Full Text] [Related]
13. MDM2 mediates fibroblast activation and renal tubulointerstitial fibrosis via a p53-independent pathway.
Ye C; Tang H; Zhao Z; Lei CT; You CQ; Zhang J; Gao P; He FF; Chen S; Wang YM; Zhang C; Su H
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F760-F768. PubMed ID: 28100501
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling.
Huang F; Zhao Y; Wang Q; Hillebrands JL; van den Born J; Ji L; An T; Qin G
Front Endocrinol (Lausanne); 2019; 10():441. PubMed ID: 31333586
[TBL] [Abstract][Full Text] [Related]
15. MAD2B-mediated SnoN downregulation is implicated in fibroblast activation and tubulointerstitial fibrosis.
Tang H; Su H; Fan D; Ye C; Lei CT; Jiang HJ; Gao P; He FF; Zhang C
Am J Physiol Renal Physiol; 2016 Jul; 311(1):F207-16. PubMed ID: 27122545
[TBL] [Abstract][Full Text] [Related]
16. Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice.
Wang LH; Liu JS; Ning WB; Yuan QJ; Zhang FF; Peng ZZ; Lu MM; Luo RN; Fu X; Hu GY; Wang ZH; Tao LJ
Pharmacology; 2011; 88(1-2):88-99. PubMed ID: 21847000
[TBL] [Abstract][Full Text] [Related]
17. The effect of low-dose Continuous Erythropoietin receptor activator in an experimental model of acute Cyclosporine A induced renal injury.
Meerwein C; Korom S; Arni S; Inci I; Weder W; Jungraithmayr W
Eur J Pharmacol; 2011 Dec; 671(1-3):113-9. PubMed ID: 21968143
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of SIRT2 Alleviates Fibroblast Activation and Renal Tubulointerstitial Fibrosis via MDM2.
He FF; You RY; Ye C; Lei CT; Tang H; Su H; Zhang C
Cell Physiol Biochem; 2018; 46(2):451-460. PubMed ID: 29614506
[TBL] [Abstract][Full Text] [Related]
19. The renal TGF-beta system in the db/db mouse model of diabetic nephropathy.
Cohen MP; Sharma K; Guo J; Eltayeb BO; Ziyadeh FN
Exp Nephrol; 1998; 6(3):226-33. PubMed ID: 9639038
[TBL] [Abstract][Full Text] [Related]
20. Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: a potential target for preventing renal fibrosis.
Yokoi H; Sugawara A; Mukoyama M; Mori K; Makino H; Suganami T; Nagae T; Yahata K; Fujinaga Y; Tanaka I; Nakao K
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S134-8. PubMed ID: 11576939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
